ATH 25.0% 0.3¢ alterity therapeutics limited

phase iib trial of its lead alzheimer's diseas

  1. 2,513 Posts.
    lightbulb Created with Sketch. 131
    Bit of repetition here.

    http://www.bloomberg.com/apps/news?pid=conewsstory&tkr=PRAN%3AUS&sid=aPh0BoZT16Ck
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.